AGAleksandra Gos

Aleksandra Gos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Gos has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 July 2015
      • Vol. 8  (7) , 8487-93

    Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.

    by Monika Jurkowska, Aleksandra Gos, Konrad Ptaszyński, Wanda Michej, Andrzej Tysarowski, Renata Zub, Janusz A Siedlecki, Piotr Rutkowski

    The study compares detection rates of oncogenic BRAF mutations in a homogenous group of 236 FFPE cutaneous melanoma lymph node metastases, collected in one cancer center. BRAF mutational status was verified by two independent in-house PCR/Sanger sequencing tests, and the Cobas® 4800 BRAF V600 Mutation Test. The best of two sequencing approaches returned results for 230/236 samples. In 140 (60.9%), the mutation in codon 600 of BRAF was found. 91.4% of all mutated cases (128 samples) represented p.V600E. Both Sanger-based tests gave reproducible results although they differed significantly in the percentage of amplifiable samples: 230/236 to 109/143. Cobas generated results in all 236 cases, mutations changing codon V600 were detected in 144 of them (61.0%), including 5 not amplifiable and 5 negative in the standard sequencing. However, 6 cases positive in sequencing turned out to be negative in Cobas. Both tests provided us with the same BRAF V600 mutational status in 219 out of 230 cases with valid results (95.2%). The total BRAF V600 mutation detection rate didn't differ significantly between the two methodological approaches (60.9% vs. 61.0%). Sequencing was a reproducible method of V600 mutation detection and more powerful to detect mutations other than p.V600E, while Cobas test proved to be less susceptible to the poor DNA quality or investigator's bias. The study underlined an important role of pathologists in quality assurance of molecular diagnostics.


  • Open Access

    Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site

    by Aleksandra Gos, Monika Jurkowska, Alexander van Akkooi, Caroline Robert, Hanna Kosela-Paterczyk, Senada Koljenović, Nyam Kamsukom, Wanda Michej, Arkadiusz Jeziorski, Piotr Pluta, et al.

    Melanoma of unknown primary site (MUP) is not a completely understood entity with nodal metastases as the most common first clinical manifestation. The aim


  • Open Access

    Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome

    by Piotr Rutkowski, Aleksandra Gos, Monika Jurkowska, Tomasz Świtaj, Wirginiusz Dziewirski, Marcin Zdzienicki, Konrad Ptaszyński, Wanda Michej, Andrzej Tysarowski, Janusz A. Siedlecki

    The aim of the present study was to evaluate the frequency and type of oncogenic v‑raf murine sarcoma viral oncogene homolog B1 (BRAF)/neuroblastoma RAS viral (v‑ras) oncogene homolog (NRAS) mutations in cutaneous melanoma with clinically detected nodal metastases (stage IIIB and C) in relation to clinicopathological features and outcome. The clinicopathological data of 250 patients following therapeutic lymphadenectomy (LND) between 1995 and 2010, as well as BRAF/NRAS mutational status in corresponding nodal metastases, were analyzed. The median follow‑up time was 53 months. BRAF mutations were detected in 154 (62%) cases (141 p.V600E, nine p.V600K and four others) and mutually exclusive NRAS mutations were detected in 42 (17%) cases. The presence of a BRAF mutation was found to correlate with patients of a younger age. The five‑year overall survival (OS) rate was 33 and 43% for LND and primary tumor excision, respectively, and the five‑year disease‑free survival (DFS) rate for LND was 25%. No correlation was identified between BRAF/NRAS mutational status and RFS or OS (calculated from the date of the LND and primary tumor excision); for BRAF‑ and NRAS‑mutated melanoma, the prognosis was the same for patients with wild‑type (WT) melanoma. The important factors which had a negative impact on OS and DFS were as follows: Male gender, >1 metastatic lymph node and extracapsular extension of nodal metastases. The interval between the diagnosis of the initial melanoma to regional nodal metastasis (median, 10 months) was not significantly different between BRAF‑mutant and ‑WT patients. Our largest comprehensive molecular analysis of clinical stage III melanoma revealed that BRAF and NRAS mutational status is not a prognostic marker in stage III melanoma patients with macroscopic nodal involvement, but may have implications for potential adjuvant therapy.